Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Respiratory Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Respir Care. 2019 Apr;64(4):453-461. doi: 10.4187/respcare.06345. Epub 2019 Jan 22.
There has been a growing trend toward delivering aerosolized medications using high-flow nasal cannula (HFNC). In some cases, patients who do not require high-flow oxygen to maintain adequate oxygenation may benefit from aerosol delivery while receiving low-flow oxygen via HFNC. The objective of this study was to quantify and compare the relative pulmonary and systemic delivery of salbutamol, with 2 different nebulizers, in patients with COPD receiving low-flow oxygen therapy through an HFNC.
Subjects were randomized to receive study doses of 5 mg salbutamol nebulized by either a jet nebulizer or a vibrating mesh nebulizer with a T-piece or spacer on days 1, 3, and 5 of admission. Subjects using the large spacer also received 2 puffs (100 μg each) of salbutamol via a pressurized metered-dose-inhaler prior to the nebulizer dose. Urinary salbutamol excretion 30 min post-inhalation and pooled samples of urinary salbutamol excretion up to 24 h post-inhalation were measured. On day 2, ex vivo studies were performed with salbutamol collected on filters placed between the HFNC and nebulizer, with drug eluted from filters and analyzed to determine inhaled dose.
Twelve subjects (6 females), age 51.3 ± 11.2 y, were included. The vibrating mesh nebulizer demonstrated higher urinary salbutamol excretion at 30 min and 24 h post-inhalation compared to a jet nebulizer ( = .001 and = .02, respectively). No significant difference was found between the T-piece and large-spacer configurations, even though the spacer provided a significantly larger emitted aerosol dose at the opening of the HFNC ( = .002).
Aerosolized medication could be efficiently combined with low-flow oxygen, via HFNC, in COPD subjects without the need to interrupt the gas supply. The vibrating mesh nebulizer delivered larger doses to subjects compared to the jet nebulizer. However, there was no benefit of using the large spacer with HFNC in low-flow delivery, because the small inner diameter of the HFNC does not allow larger aerosol droplet sizes (preserved by the spacer) to reach the subject.
越来越多的人倾向于通过高流量鼻导管(HFNC)输送雾化药物。在某些情况下,不需要高流量氧气来维持充分氧合的患者在通过 HFNC 接受低流量氧气治疗的同时,可能会受益于雾化药物输送。本研究的目的是定量和比较在接受 HFNC 低流量氧气治疗的 COPD 患者中,使用 2 种不同雾化器输送沙丁胺醇的肺内和全身相对输送。
患者在入院第 1、3 和 5 天随机接受 5mg 沙丁胺醇雾化治疗,使用射流雾化器或振动网孔雾化器,通过 T 型件或带有大储雾罐的 spacer。使用大储雾罐的患者在雾化器给药前还通过压力定量吸入器吸入 2 喷(每喷 100μg)沙丁胺醇。雾化后 30min 测量尿中沙丁胺醇排泄量,雾化后 24h 内收集尿液进行混合样品测量。第 2 天,在 HFNC 和雾化器之间放置的过滤器上收集沙丁胺醇,洗脱药物后分析以确定吸入剂量,进行体外研究。
12 名患者(6 名女性),年龄 51.3±11.2 岁,纳入研究。与射流雾化器相比,振动网孔雾化器在雾化后 30min 和 24h 时尿中沙丁胺醇排泄量更高( =.001 和 =.02,分别)。尽管大储雾罐在 HFNC 开口处提供了明显更大的气溶胶发射剂量,但 T 型件和大储雾罐构型之间没有差异( =.002)。
在 COPD 患者中,无需中断气体供应,即可通过 HFNC 有效将雾化药物与低流量氧气联合使用。与射流雾化器相比,振动网孔雾化器向患者输送的剂量更大。然而,在低流量输送中,HFNC 中使用大储雾罐并没有获益,因为 HFNC 的小内径不允许更大的气溶胶液滴尺寸(由储雾罐保留)到达患者。